# Beijing Baicare Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-baicare-biotechnology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.bai-care.com
- Total disclosed funding: $9.4M
- Latest round: Series B (Jul 12, 2019)
- Investors on record: 3

## About

Based in Beijing, China and established in 2013, Beijing Baicare Biotechnology Co., Ltd. is a biomedical enterprise that focuses on the research and development, production, and sales of clinical test reagents and instruments. It has 110 million square meters of R&D and production centers in Beijing and Tianjin. Besides, it has a number of honors, including Zhongguancun International Frontier Technology Innovation Competition TOP10 and HICOOL Global Entrepreneurship Competition. In 2016, its GMP clean workshop was completed, with mass production conditions. In 2019, its nucleic acid analysis system was licensed by CDFA.

The company has developed and designed a series of products such as ultra fast QPCR system, multi-index nucleic acid testing (NAT) system, automatic nucleic acid testing (NAT) system, microfluidic chip for detecting the multiple respiratory tracts,  and gynecological and cerebrospinal fluid infections. Its nucleic acid testing system contains features such as accurate results, fast and simple.

## Funding rounds

- Series B, Jul 12, 2019, $9.4M — Shanghai Jianyi Private Equity Fund Management, K2VC, LYFE Capital
- Series A, Jan 17, 2018 — K2VC, LYFE Capital

## Investors

- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A, Series B
- LYFE Capital — Series A, Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B